New agents for treating dry eye syndrome

Simon E. Skalicky*, Con Petsoglou, Avinash Gurbaxani, Clare L. Fraser, Peter McCluskey

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

15 Citations (Scopus)


Dry eye syndrome (DES) is characterized by an inadequate volume and/or quality of tears resulting in chronic ocular surface irritation and inflammation. Affecting up to 30 % of adults, DES has a considerable impact on visual function and quality of life. DES may complicate allergic ocular disease and allergy medication may exacerbate DES. The pathophysiology of DES involves osmotic, mechanical and inflammatory insults to the tear film, epithelium and subepithelial nerve plexus. Various immune-related molecular targets have been the focus of research aimed at developing new therapeutic agents for treating DES. This article provides an overview of established, new and future agents for treating DES.

Original languageEnglish
Pages (from-to)322-328
Number of pages7
JournalCurrent Allergy and Asthma Reports
Issue number3
Publication statusPublished - Jun 2013
Externally publishedYes


  • Anti-inflammatory agents
  • Artificial tears
  • Corticosteroids
  • Cyclosporine A
  • Dry eye syndrome
  • Essential fatty acids
  • New agents
  • NSAIDs
  • Ocular lubricants
  • Secretagogues
  • Topical therapies
  • Treatment


Dive into the research topics of 'New agents for treating dry eye syndrome'. Together they form a unique fingerprint.

Cite this